FDA Issues Safety Alert: Potential Vitamin B7 Lab Test InterferenceNovember 30, 2017
U.S. Food and Drug Administration (FDA)
Posted November 28, 2017
AUDIENCE: Laboratory, Health Professional, Patient
ISSUE: The FDA is alerting the public, health care providers, lab personnel, and lab test developers that biotin can significantly interfere with certain lab tests and cause incorrect test results which may go undetected.
Biotin in blood or other samples taken from patients who are ingesting high levels of biotin in dietary supplements can cause clinically significant incorrect lab test results. The FDA has seen an increase in the number of reported adverse events, including one death, related to biotin interference with lab tests.
Biotin in patient samples can cause falsely high or falsely low results, depending on the test. Incorrect test results may lead to inappropriate patient management or misdiagnosis. For example, a falsely low result for troponin, a clinically important biomarker to aid in the diagnosis of heart attacks, may lead to a missed diagnosis and potentially serious clinical implications. The FDA has received a report that one patient taking high levels of biotin died following falsely low troponin test results when a troponin test known to have biotin interference was used.News. Bookmark the permalink. ← NMG Speaks at G2 Lab Institute 2017: Conference Ends With Optimistic Outlook for Laboratories Labs Sue CMS Over Planned Cut →